Literature DB >> 18025880

End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004.

Gregory M Lucas1, Shruti H Mehta, Mohamed G Atta, Gregory D Kirk, Noya Galai, David Vlahov, Richard D Moore.   

Abstract

BACKGROUND: HIV-infected African-Americans are at increased risk of end-stage renal disease requiring renal replacement therapy (RRT).
OBJECTIVES: To compare the incidence of RRT in HIV-infected and HIV-seronegative African-Americans and describe temporal trends in RRT and chronic kidney disease (CKD) in HIV infection.
DESIGN: Cohort study in Baltimore including 4509 HIV-infected and 1746 HIV-seronegative African-Americans.
METHODS: Incident RRT was defined by matching participant identifiers with the US Renal Data System; CKD was defined as an estimated glomerular filtration rate < 60 ml/min per 1.73m for >/= 3 months. Standardized incidence ratios (SIR) and 95% confidence intervals (CI) were calculated by indirect adjustment. Risk factors for RRT were assessed by person-time methods and Poisson regression.
RESULTS: RRT was initiated in 24 HIV-seronegative subjects over 13 415 person-years of follow-up (SIR, 2.3; 95% CI, 1.5-3.4), in 51 HIV-infected participants without AIDS over 10 780 person-years (SIR, 6.9; 95% CI, 5.1-9.0), and in 125 participants with AIDS over 9833 person-years. SIR, 16.1; 95% CI, 13.4-19.2). In HIV-infected African-Americans, RRT incidences were 5.8 and 9.7/1000 person-years in the pre-HAART and HAART eras, respectively (adjusted rate ratio 1.2; 95% CI, 0.8-1.9). In supplementary analyses, CKD incidence declined significantly in the HAART era compared with pre-HAART, but the CKD period prevalence increased.
CONCLUSIONS: Nearly 1% of HIV-infected African-Americans initiated RRT annually, a rate that was similar in the HAART and pre-HAART eras. While new cases of CKD decreased, the prevalence of CKD increased in the HAART era, primarily because survival in those with HIV-associated CKD has improved.

Entities:  

Mesh:

Year:  2007        PMID: 18025880     DOI: 10.1097/QAD.0b013e32827038ad

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  65 in total

1.  HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group.

Authors:  Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

Review 2.  Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene.

Authors:  Marina Núñez; Anita M Saran; Barry I Freedman
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

Review 3.  The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.

Authors:  Christina M Wyatt; Carlos Malvestutto; Steven G Coca; Paul E Klotman; Chirag R Parikh
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

Review 4.  Identifying the appropriate comparison group for HIV-infected individuals.

Authors:  Cherise Wong; Keri Althoff; Stephen J Gange
Journal:  Curr Opin HIV AIDS       Date:  2014-07       Impact factor: 4.283

5.  Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study.

Authors:  Alison G Abraham; Annie Darilay; Heather McKay; Joseph B Margolick; Michelle M Estrella; Frank J Palella; Robert Bolan; Charles R Rinaldo; Lisa P Jacobson
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

Review 6.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  The nephrotoxic effects of HAART.

Authors:  Hassane Izzedine; Marianne Harris; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

8.  The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy.

Authors:  Christina M Wyatt; Susan Morgello; Rebecca Katz-Malamed; Catherine Wei; Mary E Klotman; Paul E Klotman; Vivette D D'Agati
Journal:  Kidney Int       Date:  2008-12-03       Impact factor: 10.612

9.  Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Authors:  Amanda Mocroft; Christina Wyatt; Lynda Szczech; Jacquie Neuhaus; Wafaa El-Sadr; Russell Tracy; Lewis Kuller; Michael Shlipak; Brian Angus; Harting Klinker; Michael Ross
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

10.  Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV.

Authors:  M Bradley Drummond; Gregory D Kirk; Erin P Ricketts; Meredith C McCormack; J Christian Hague; John F McDyer; Shruti H Mehta; Eric A Engels; Robert A Wise; Christian A Merlo
Journal:  BMC Pulm Med       Date:  2010-05-11       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.